About Pharvaris N.V.
https://pharvaris.comPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
CEO
Berndt Axel Edvard Modig
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 43
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
GENERAL ATLANTIC, L.P.
Shares:8.03M
Value:$205.84M
FMR LLC
Shares:6.4M
Value:$164.01M
FORESITE CAPITAL MANAGEMENT IV, LLC
Shares:4.78M
Value:$122.48M
Summary
Showing Top 3 of 86
About Pharvaris N.V.
https://pharvaris.comPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $39.66M ▼ | $-37.14M ▲ | 0% | $-0.6 ▲ | $-37.21M ▲ |
| Q2-2025 | $0 | $40.37M ▲ | $-45.48M ▲ | 0% | $-0.83 ▲ | $-40.27M ▲ |
| Q1-2025 | $0 | $-42.19M ▼ | $-46.34M ▼ | 0% | $-0.85 ▼ | $-42.08M ▼ |
| Q4-2024 | $0 | $48M ▲ | $-37.08M ▲ | 0% | $-0.64 ▲ | $-35.64M ▲ |
| Q3-2024 | $0 | $37.9M | $-41.71M | 0% | $-0.77 | $-37.86M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $329.29M ▲ | $338.9M ▲ | $26.66M ▲ | $312.24M ▲ |
| Q2-2025 | $199.57M ▼ | $209.81M ▼ | $25.47M ▲ | $184.34M ▼ |
| Q1-2025 | $236.5M ▼ | $248.06M ▼ | $22.73M ▼ | $225.34M ▼ |
| Q4-2024 | $280.73M ▼ | $291.37M ▼ | $23.61M ▲ | $267.76M ▼ |
| Q3-2024 | $305.19M | $313.18M | $16.39M | $296.79M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-37.32M ▲ | $-30.67M ▼ | $-18.71K ▼ | $160.43M ▲ | $129.71M ▲ | $-30.69M ▼ |
| Q2-2025 | $-45.28M ▲ | $-29.98M ▲ | $16.64K ▲ | $-22.9K ▲ | $-36.92M ▲ | $-29.96M ▲ |
| Q1-2025 | $-46.04M ▼ | $-38.47M ▼ | $-161K ▼ | $-75.45K ▼ | $-44.23M ▼ | $-38.63M ▼ |
| Q4-2024 | $-33.52M ▲ | $-34.95M ▼ | $-160.92K ▲ | $566.16K ▼ | $-24.47M ▲ | $-35.11M ▼ |
| Q3-2024 | $-41.48M | $-33.26M | $-306.32K | $991.93K | $-38.38M | $-33.57M |
CEO
Berndt Axel Edvard Modig
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 43
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Oppenheimer
Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
GENERAL ATLANTIC, L.P.
Shares:8.03M
Value:$205.84M
FMR LLC
Shares:6.4M
Value:$164.01M
FORESITE CAPITAL MANAGEMENT IV, LLC
Shares:4.78M
Value:$122.48M
Summary
Showing Top 3 of 86